FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003121381> ?p ?o ?g. }

• W2003121381 endingPage "1251" @default.
• W2003121381 startingPage "1247" @default.
• W2003121381 abstract "The activation and proliferation of peripheral blood mononuclear cells (PBMNCs) are complex processes involving several surface molecules, cell secretion and response to cytokines. This paper investigates the immunomodulatory effect of prophylactic treatment with interferon alpha 2b (IFN-alpha 2b) upon the blastogenic response of PBMNCs from patients with superficial transitional cell carcinoma (STCC) of the bladder to mitogenic signals that interact with surface molecules [phytohaemagglutinin, PHA and anti-CD3 monoclonal antibodies, (MAbs)]. PBMNCs from the patients were studied prior to the transurethral resection (TUR) of the tumour, during the second month of prophylactic intravesical instillation of IFN-alpha 2b and 3 and 6 months after finishing the instillation treatment. The [3H]thymidine uptake of PBMNCs from 17 patients with STCC of the bladder after 5 days of PHA and anti-CD3 MAb stimulus was found to be significantly lower than that of healthy controls (P < 0.05). The addition of interleukin 2 (IL-2) to the culture medium did not correct this defective proliferative response to PHA and the anti-CD3 MAb. There were no significant differences between IL-2 production in PBMNCs from STCC patients after stimulation with PHA and in PBMNCs from healthy controls (P > 0.05). Patients without evidence of recurrence showed a significantly enhanced proliferative response in PBMNC to PHA and anti-CD3 MAb after intravesical prophylactic treatment with interferon-alpha 2b in the follow-up examinations 3 and 6 months after treatment (P < 0.01). However, three patients had evidence of tumour recurrence, and they showed no enhancement of the PBMNC proliferative response to these mitogens in the same examinations. In conclusion, the prophylactic intracavitary treatment of STCC with IFN-alpha 2b may induce a systemic immunomodulatory effect which is associated to the clinical evolution of the disease." @default.
• W2003121381 created "2016-06-24" @default.
• W2003121381 creator A5000365259 @default.
• W2003121381 creator A5006007291 @default.
• W2003121381 creator A5013273929 @default.
• W2003121381 creator A5031135111 @default.
• W2003121381 creator A5041158020 @default.
• W2003121381 creator A5056466530 @default.
• W2003121381 creator A5079243550 @default.
• W2003121381 creator A5079425003 @default.
• W2003121381 date "1994-12-01" @default.
• W2003121381 modified "2023-10-18" @default.
• W2003121381 title "Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation" @default.
• W2003121381 cites W1514412248 @default.
• W2003121381 cites W1661591147 @default.
• W2003121381 cites W1933619351 @default.
• W2003121381 cites W1969800450 @default.
• W2003121381 cites W1970037380 @default.
• W2003121381 cites W1981541848 @default.
• W2003121381 cites W1983205909 @default.
• W2003121381 cites W1984755443 @default.
• W2003121381 cites W1997607588 @default.
• W2003121381 cites W1997738769 @default.
• W2003121381 cites W2003913995 @default.
• W2003121381 cites W2005588999 @default.
• W2003121381 cites W2021064854 @default.
• W2003121381 cites W2036275492 @default.
• W2003121381 cites W2047653672 @default.
• W2003121381 cites W2058331779 @default.
• W2003121381 cites W2071992849 @default.
• W2003121381 cites W2078254067 @default.
• W2003121381 cites W2079959266 @default.
• W2003121381 cites W2083787541 @default.
• W2003121381 cites W2098476406 @default.
• W2003121381 cites W2118511255 @default.
• W2003121381 cites W2118857294 @default.
• W2003121381 cites W2160736132 @default.
• W2003121381 cites W2171635063 @default.
• W2003121381 cites W2336213711 @default.
• W2003121381 cites W2408301264 @default.
• W2003121381 cites W2410336101 @default.
• W2003121381 cites W2413597805 @default.
• W2003121381 cites W2419114054 @default.
• W2003121381 cites W2429532617 @default.
• W2003121381 cites W2432371414 @default.
• W2003121381 cites W2441091624 @default.
• W2003121381 cites W2460892140 @default.
• W2003121381 cites W2472545738 @default.
• W2003121381 doi "https://doi.org/10.1038/bjc.1994.481" @default.
• W2003121381 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2033676" @default.
• W2003121381 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7981084" @default.
• W2003121381 hasPublicationYear "1994" @default.
• W2003121381 type Work @default.
• W2003121381 sameAs 2003121381 @default.
• W2003121381 citedByCount "24" @default.
• W2003121381 countsByYear W20031213812019 @default.
• W2003121381 crossrefType "journal-article" @default.
• W2003121381 hasAuthorship W2003121381A5000365259 @default.
• W2003121381 hasAuthorship W2003121381A5006007291 @default.
• W2003121381 hasAuthorship W2003121381A5013273929 @default.
• W2003121381 hasAuthorship W2003121381A5031135111 @default.
• W2003121381 hasAuthorship W2003121381A5041158020 @default.
• W2003121381 hasAuthorship W2003121381A5056466530 @default.
• W2003121381 hasAuthorship W2003121381A5079243550 @default.
• W2003121381 hasAuthorship W2003121381A5079425003 @default.
• W2003121381 hasBestOaLocation W20031213812 @default.
• W2003121381 hasConcept C114684123 @default.
• W2003121381 hasConcept C126322002 @default.
• W2003121381 hasConcept C137061746 @default.
• W2003121381 hasConcept C159654299 @default.
• W2003121381 hasConcept C167672396 @default.
• W2003121381 hasConcept C202751555 @default.
• W2003121381 hasConcept C203014093 @default.
• W2003121381 hasConcept C24998067 @default.
• W2003121381 hasConcept C2776178377 @default.
• W2003121381 hasConcept C2778690821 @default.
• W2003121381 hasConcept C2780050583 @default.
• W2003121381 hasConcept C2909179924 @default.
• W2003121381 hasConcept C542903549 @default.
• W2003121381 hasConcept C55493867 @default.
• W2003121381 hasConcept C71924100 @default.
• W2003121381 hasConcept C86803240 @default.
• W2003121381 hasConcept C8891405 @default.
• W2003121381 hasConceptScore W2003121381C114684123 @default.
• W2003121381 hasConceptScore W2003121381C126322002 @default.
• W2003121381 hasConceptScore W2003121381C137061746 @default.
• W2003121381 hasConceptScore W2003121381C159654299 @default.
• W2003121381 hasConceptScore W2003121381C167672396 @default.
• W2003121381 hasConceptScore W2003121381C202751555 @default.
• W2003121381 hasConceptScore W2003121381C203014093 @default.
• W2003121381 hasConceptScore W2003121381C24998067 @default.
• W2003121381 hasConceptScore W2003121381C2776178377 @default.
• W2003121381 hasConceptScore W2003121381C2778690821 @default.
• W2003121381 hasConceptScore W2003121381C2780050583 @default.
• W2003121381 hasConceptScore W2003121381C2909179924 @default.
• W2003121381 hasConceptScore W2003121381C542903549 @default.
• W2003121381 hasConceptScore W2003121381C55493867 @default.
• W2003121381 hasConceptScore W2003121381C71924100 @default.

• next